Merck & Co., Inc. (NYSE:MRK) has been on a strong recovery run, gaining 23% over the past year and 8% year-to-date, though the stock has pulled back some, now well below its 52-week high of $125.14.

Merck & Co. Inc. (NYSE:MRK) ranks among the 14 safe stocks to buy now for a starter stock portfolio. Merck & Co. Inc. (NYSE:MRK) ranks among the 14 safe stocks to buy now for a starter stock portfolio ...

A giant in the healthcare space, Merck (NYSE:MRK) shares are up 13.5% year-to-date and trading near $119.47, yet retail sentiment on Reddit has slipped from a bullish 63 over the past quarter to a ...

Shares of Merck & Co. Inc. MRK slipped 1.30% to $119.83 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.94% to 6,816.63 ...

Merck & Co. ( MRK) shares clocked seven straight sessions of gains, as the stock was up 0.2% at $124.1 on Tuesday. The global healthcare company gained 2% in the preceding six sessions. The stock has ...

We recently published 8 Stocks on Jim Cramer’s Radar. Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s radars. Pharma giant Merck & Co., Inc. (NYSE:MRK)’s shares are up by 1.9% ...

Merck (NYSE:MRK) reported a series of positive late stage clinical trial results for oncology and HIV therapies, including new Phase 3 data for KEYTRUDA and WELIREG regimens in kidney, ovarian, and ...

Merck MRK is set to report its fourth-quarter and full-year 2025 earnings on Feb. 3, before market open. The Zacks Consensus Estimate for fourth-quarter sales and earnings is pegged at $16.19 billion ...